faq

Q:	What protocol should I use for Nucleofection® of patient derived blood samples, e.g. leukemia or lymphoma cells?
A:	Unfortunately, we do not have a ready-to-use protocol for Chronic lymphocytic leukemia (CLL) or other blood cell derived cancer cells. The cells often have a chromosomal aberration and show the properties of a cell line. Therefore we suggest to perform an optimization with our Cell Line Optimization Kit. This should also be done for each individual donor. To see examples check our knowledge center for AML, CML, and ALL cells. You may also find the following reference helpful: (Merkerova et al., reproduced from Mol Biol Rep (2007) 34:27-33).

What protocol should I use for Nucleofection® of patient derived blood samples, e.g. leukemia or lymphoma cells?

Unfortunately, we do not have a ready-to-use protocol for Chronic lymphocytic leukemia (CLL) or other blood cell derived cancer cells.

The cells often have a chromosomal aberration and show the properties of a cell line. Therefore we suggest to perform an optimization with our Cell Line Optimization Kit. This should also be done for each individual donor. To see examples check our knowledge center for AML, CML, and ALL cells.

You may also find the following reference helpful: (Merkerova et al., reproduced from Mol Biol Rep (2007) 34:27-33).

Categories:

Transfection

Research Areas:

Cancer Research/Cell Biology

Gene Expression